Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01673438
Recruitment Status : Completed
First Posted : August 28, 2012
Last Update Posted : April 21, 2014
Sponsor:
Information provided by (Responsible Party):
CytRx

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014